首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Ejhaem

缩写:

ISSN:2688-6146

e-ISSN:2688-6146

IF/分区:1.3/Q4

文章目录 更多期刊信息

共收录本刊相关文章索引1401条
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Emmanuelle Bernit,Marc Romana,Scylia Alexis-Fardini et al. Emmanuelle Bernit et al.
We investigate risk factors for hospitalization and difference between sickle cell syndromes in a cohort of COVID-19 sickle cell disease (SCD) adult patients managed in the Reference Center of Guadeloupe. We retrospectively collected data o...
Vikram Premkumar,Samuel Pan,Suzanne Lentzsch et al. Vikram Premkumar et al.
Daratumumab is approved for use in newly diagnosed and relapsed/refractory multiple myeloma (MM), however the patients most likely to benefit from its addition to standard anti-myeloma therapy is unclear. This meta-analysis included 2340 ne...
Hisashi Ishida,Yuji Miyajima,Nobuyuki Hyakuna et al. Hisashi Ishida et al.
Background: Philadelphia-negative (Ph-negative) myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are exceptionally rare during childho...
Baptiste Le Calvez,Yannick Le Bris,Guillaume Herbreteau et al. Baptiste Le Calvez et al.
Multiple myeloma (MM) is still considered incurable and new therapeutic approaches are therefore needed. Deep-sequencing analysis revealed the presence of BRAF mutations in up to 15% of patients. The clinical experience of BRAF-targeted the...
Elizabeth H Phillips,Catherine Burton,Amy A Kirkwood et al. Elizabeth H Phillips et al.
Introduction: Outcomes after frontline treatment of Burkitt lymphoma (BL) have improved with the introduction of dose-intense chemotherapy regimens, such as CODOX-M/IVAC. While rituximab has increased survival rates for m...
Shifang Wang,Sai Prasad Desikan,Jay Jeffrey et al. Shifang Wang et al.
Advent of tyrosine kinase inhibitors (TKI) have revolutionized therapy of chronic myeloid leukemia. Imatinib was the first agent utilized in the therapy of CML. Nilotinib, a second generation TKI, results in an increase in number of patient...